Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-229-5872
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$21.70 million
Profitability
Miscellaneous
Employees124
Next Earnings Date11/1/2019 (Estimated)
OptionableOptionable
Epizyme (NASDAQ:EPZM) Frequently Asked Questions
What is Epizyme's stock symbol?
Epizyme trades on the NASDAQ under the ticker symbol "EPZM."
How were Epizyme's earnings last quarter?
Epizyme Inc (NASDAQ:EPZM) announced its quarterly earnings data on Friday, August, 9th. The biopharmaceutical company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.51) by $0.02. The biopharmaceutical company had revenue of $5.90 million for the quarter, compared to analyst estimates of $0.32 million. The company's revenue for the quarter was down 50.8% on a year-over-year basis. During the same period last year, the firm posted ($0.42) EPS. View Epizyme's Earnings History.
When is Epizyme's next earnings date?
What price target have analysts set for EPZM?
8 analysts have issued 12-month price objectives for Epizyme's stock. Their predictions range from $11.00 to $25.00. On average, they expect Epizyme's share price to reach $17.57 in the next year. This suggests a possible upside of 75.2% from the stock's current price. View Analyst Price Targets for Epizyme.
What is the consensus analysts' recommendation for Epizyme?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Epizyme.
Has Epizyme been receiving favorable news coverage?
News coverage about EPZM stock has been trending negative on Monday, InfoTrie reports. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Epizyme earned a media sentiment score of -2.6 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Epizyme.
Are investors shorting Epizyme?
Epizyme saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 8,340,000 shares, an increase of 5.3% from the August 30th total of 7,920,000 shares. Based on an average trading volume of 653,500 shares, the short-interest ratio is presently 12.8 days. Currently, 10.9% of the shares of the stock are sold short. View Epizyme's Current Options Chain.
Who are some of Epizyme's key competitors?
Some companies that are related to Epizyme include United Therapeutics (UTHR), Blueprint Medicines (BPMC), FibroGen (FGEN), Evotec (EVTCY), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), Allakos (ALLK), Taro Pharmaceutical Industries (TARO), Nektar Therapeutics (NKTR), Global Blood Therapeutics (GBT), Alkermes (ALKS), Emergent Biosolutions (EBS), Reata Pharmaceuticals (RETA), Genmab A/S (GMAB) and Myokardia (MYOK).
What other stocks do shareholders of Epizyme own?
Who are Epizyme's key executives?
Epizyme's management team includes the folowing people:
- Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 51)
- Mr. Matthew E. Ros, Chief Strategy & Bus. Officer and Principal Financial Officer (Age 52)
- Dr. H. Robert Horvitz, Co-Founder & Chairman of the Scientific Advisory Board
- Dr. Yi Zhang, Scientific Co-Founder & Member of The Scientific Advisory Board
- Mr. Joseph Beaulieu, Controller, Treasurer & Principal Accounting Officer (Age 38)
How do I buy shares of Epizyme?
Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Epizyme's stock price today?
One share of EPZM stock can currently be purchased for approximately $10.03.
How big of a company is Epizyme?
Epizyme has a market capitalization of $913.13 million and generates $21.70 million in revenue each year. The biopharmaceutical company earns $-123,630,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Epizyme employs 124 workers across the globe.View Additional Information About Epizyme.
What is Epizyme's official website?
How can I contact Epizyme?
Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]
MarketBeat Community Rating for Epizyme (NASDAQ EPZM)
MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote "Outperform" if you believe EPZM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPZM will underperform the S&P 500 over the long term. You may vote once every thirty days.
